Lotrimin Ultra (butenafine HCl)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Butenafine hydrochloride is a synthetic benzylamine antifungal agent.
Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine is structurally and pharmacologically related to allylamine antifungals (e.g., naftifine, terbinafine).
The exact mechanism of action of butenafine's antifungal activity has not been fully determined. Butenafine presumably exerts its antifungal activity by altering cellular membranes, resulting in increased membrane permeability, and growth inhibition. Although the exact mechanism of action of butenafine has not been fully determined, it has been suggested that the antifungal activity of the drug may result from interference with ergosterol synthesis.
The drug appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene monooxygenase (squalene 2,3-epoxidase), which results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene (the usual substrate of the enzyme) in the cells. Butenafine, like allylamine derivatives, appears to affect sterol biosynthesis at an earlier stage than do imidazole derivatives.
Butenafine may be fungicidal in certain concentrations or against susceptible organisms (e.g., dermatophytes). Butenafine is active in vitro against Epidermophyton floccosum, Microsporum canis, Trichophyton mentagrophytes, T. rubrum, Malassezia furfur (Pityrosporum orbiculare or P. ovale), and Sporothrix schenckii. The drug also is active against some yeasts, including Candida albicans and C. parapsilosis.
USES: This medication is used to treat a variety of fungal skin infections such as ringworm, athlete's foot, and jock itch. This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Butenafine is an antifungal that works by preventing the growth of fungus.
Do not use this medication for the treatment of fungal nail infections.
Generic name: butenafine HCl
Pronunciation: (bue-TEN-a-feen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Lotrimin Ultra
Indications
The following indications are listed for Lotrimin Ultra:
- Tinea Corporis
- Tinea Cruris
- Tinea Pedis
- Tinea Versicolor
Also known as: Corporeal Ringworm, Dermatomycosis Pedis, Dhobie Itch, Eczema Marginatum, Jock Itch, Pityriasis Versicolor, Tinea Circinata, Tinea Furfuracea, Tinea Glabrosa, Tinea Inguinalis, Tinea Of The Foot.
Dosing
No dosing information is available for this tab.
Butenafine hydrochloride is applied topically to the skin as a 1% cream.
Butenafine cream should not be applied to eyes. Contact with the mouth, eyes, and other mucous membranes should be avoided.
Butenafine should not be applied to scalp or nail infections.
Prior to application of the cream, the affected areas should be cleansed with soap and water and dried thoroughly. The cream is then applied and massaged gently into the affected areas. Hands should be washed after the application process.
Occlusive dressings or wrappings should not be used.
When used for the treatment of interdigital tinea pedis (athlete's foot), special attention should be paid to applying to spaces between the toes. In addition, patients with tinea pedis should wear well-fitting, ventilated shoes and change their shoes and socks at least once daily.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed to date with butenafine.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to butenafine or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Burning/stinging, itching, and worsening of condition reported in 1% of patients in clinical studies.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy not established in children younger than 12 years of age. Use in children 12-16 years of age is supported by evidence from adequate and well-controlled studies in adults.
Category B. (See Users Guide.)
Not known whether butenafine is distributed into milk following topical administration. Use with caution and avoid applying the drug to the breast of nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.